Companies / Dogwood Therapeutics, Inc.

Dogwood Therapeutics, Inc.

Nasdaq: DWTXCIK 1818844ALPHARETTA, GA

Financials

Revenue—
Net income$-34.26M
Total debt—
Cash$13.23M
Diluted EPS$-7.13
Shares outstanding33.6M

Ownership

33.6M shares outstanding · as of May 13, 2026
0.48%Institutions
Ownership
Institutions0.48%161,467
Public float99.52%33,468,086

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 4

View all →
Insider% of sharesShares
Duncan Gregory ScottCEOCHIEF EXECUTIVE OFFICER · Director
——
Gendreau Roger MichaelCHIEF MEDICAL OFFICER
——
Grosswald RalphSVP OF OPERATIONS
——
Walsh AngelaChief Financial Officer
——

Institutional holders 11

View all →
HolderValue% of shares
Geode Capital Management, LLC$167.6K0.24%
Vanguard Group Inc$124.6K0.09%
BlackRock, Inc.$46.0K0.08%
Bank of America Corp /De$39.2K0.03%
Marshall Wace, LLP$24.8K0.03%
UBS Group AG$7.3K<0.01%
Morgan Stanley$2.0K<0.01%
Activest Wealth Management$499<0.01%
Barclays PLC$39<0.01%
Group One Trading LLC$37<0.01%

Activity

View all →
InsidersInstitutions
What insiders are doing in this stock (Form 4).
DateActorActionSecurityValueShares ΔPosition afterImpact
Mar 5, 2026Duncan Gregory Scott
CEO
GrantStock Option (right to buy)—+330K
330,000
0.98% of shares
low
Mar 5, 2026Gendreau Roger Michael
Executive
GrantStock Option (right to buy)—+83K
82,500
0.25% of shares
low
Mar 5, 2026Grosswald Ralph
Executive
GrantStock Option (right to buy)—+83K
82,500
0.25% of shares
low
Mar 5, 2026Walsh Angela
Executive
GrantStock Option (right to buy)—+83K
82,500
0.25% of shares
low

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
DWTXCommon StockEquity92829J203BBG00X0SZKJ2